US Bancorp DE Sells 4,587 Shares of Certara, Inc. (NASDAQ:CERT)

US Bancorp DE decreased its position in Certara, Inc. (NASDAQ:CERT) by 28.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,575 shares of the company’s stock after selling 4,587 shares during the period. US Bancorp DE’s holdings in Certara were worth $136,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Sei Investments Co. lifted its stake in shares of Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock valued at $12,793,000 after purchasing an additional 79,013 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in shares of Certara by 27.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after buying an additional 110,636 shares in the last quarter. Daventry Group LP grew its position in shares of Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Certara by 8.4% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 810,206 shares of the company’s stock valued at $11,221,000 after acquiring an additional 62,912 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Certara by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares during the period. Institutional investors own 73.96% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on CERT shares. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $15.92.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Trading Down 5.4 %

NASDAQ:CERT opened at $9.96 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a one year low of $9.88 and a one year high of $19.87. The company has a market cap of $1.60 billion, a PE ratio of -49.80, a PEG ratio of 5.46 and a beta of 1.51. The firm has a 50-day moving average of $10.90 and a 200-day moving average of $13.49.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. During the same period in the previous year, the company posted $0.06 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.